British Journal of Cancer

FIGURES AND TABLES

FROM:

Cancer Research UK procedures in manufacture and toxicology of radiotracers intended for Pre-phase I positron emission tomography studies in cancer patients

E O Aboagye, S K Luthra, F Brady, K Poole, H Anderson, T Jones, A Boobis, S S Burtles and P Price

BACK TO ARTICLE
Table 1 - PET radioligands and radiotracers currently being investigated/used in oncology - Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, please contact help@nature.com or the author

Table 1 - PET radioligands and radiotracers currently being investigated/used in oncology.

Full table (25K)
Table 2 - Chemical analysis and set limits on oncology radiopharmaceuticals recently analysed by the Quality Control team at the author's instituion. All samples were analysed by reversed-phase HPLC with UV detection except for 2-[18F]fluorodeoxyglucose (2-[18F]FDG) which was analysed by ion-exchange HPLC with pulsed-amperometric detection - Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, please contact help@nature.com or the author

Table 2 - Chemical analysis and set limits on oncology radiopharmaceuticals recently analysed by the Quality Control team at the author's instituion. All samples were analysed by reversed-phase HPLC with UV detection except for 2-[18F]fluorodeoxyglucose (2-[18F]FDG) which was analysed by ion-exchange HPLC with pulsed-amperometric detection.

Full table (22K)
BACK TO ARTICLE